Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Hillis’ provocative title is a reference to the way that certain simplifying assumptions that underpin the formal models on ...

Best-selling author J.B. MacKinnon is the representative plaintiff in four proposed class-action lawsuits that allege ...

Amal El-Mohtar and Max Gladstone’s This Is How You Lose The Time War is the story of two rival time travelers fighting on ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...